

## CSU IBC Meeting Approved Minutes

<b>Meeting title</b>	CSU IBC Meeting April 2026
<b>Date</b>	April 8, 2026
<b>Convened at</b>	8:35am
<b>Location</b>	TMI Rm 222
<b>Open or closed meeting (If closed, why?)</b>	The meeting was closed briefly to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
<b>Review of prior meeting minutes</b>	March 11, 2026 meeting minutes were approved as written.
<b>Adjournment</b>	9:24am
<b>Recorded by</b>	C. Johnson

### Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
<input checked="" type="checkbox"/> Jessica Ayers, Animal expert	<input type="checkbox"/> Lon Kendall, Director LAR
<input checked="" type="checkbox"/> Donald Bade, Unaffiliated	
<input type="checkbox"/> Angela Bosco-Lauth, Associate Chair	
<input checked="" type="checkbox"/> Joshua Chan, Synthetic biology	
<input checked="" type="checkbox"/> Chaoping Chen, Chair	
<input checked="" type="checkbox"/> Jason Cummings, Lab representative	
<input type="checkbox"/> Dan Frazen, Unaffiliated	
<input type="checkbox"/> Brendan Podell, Mycobacteria specialist	
<input checked="" type="checkbox"/> Ann Powers, Virology	
<input checked="" type="checkbox"/> Robyn Roberts, Plant expert	
<input checked="" type="checkbox"/> Joanie Ryan, Assistant Biosafety Director	<input checked="" type="checkbox"/> Rebecca Moritz, Biosafety Office Director*
<input checked="" type="checkbox"/> Tony Schountz, Virology	<input checked="" type="checkbox"/> Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; _9_ in attendance	*non-voting at this meeting
<b>Non-Voting Members:</b>	
<input type="checkbox"/>	
<input checked="" type="checkbox"/> Joni Van Sickle, Occupational Health Coord.	
<b>ORCC Staff (non-voting):</b>	
<input type="checkbox"/> Michelle Ramey, Assistant Compliance Coord.	<input type="checkbox"/> Sonia Aleman Rivera, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Nicole Marlenee, Biosecurity Specialist	<input checked="" type="checkbox"/> Kelly Kim, Assistant Biosafety Officer
<input type="checkbox"/> Scott Van Scotter, Biosafety Trainer	
<b>Additional Guests:</b>	
Mario Arango, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

### 1. New IBC Member

The IBC/IRE Manager introduced new committee member, Dr. Joshua Chan. Dr Chan is from the CSU School of Biomedical and Chemical Engineering and brings expertise in synthetic biology and microbial molecular biology. The committee members introduced themselves and welcomed Dr. Chan to the committee.

### 2. Review of March 11, 2026, IBC meeting minutes

The minutes were unanimously approved as written.

### 3. Agent/Project Review

<b>a. PI name/Lab</b>	<b>Stenglein Lab</b>
<b>Project Number and Title</b>	<b>19-085B: Analysis of bunyavirus reassortment</b>
<b>Project Overview</b>	The goal of this project is to develop a new way to study viral reassortment, to use it to learn more about the mechanisms that determine whether two bunyaviruses can reassort, and to acquire pilot data for an NIH proposal.
<b>Planned Modifications</b>	Generating plasmids and infectious clones
<b>Pathogen/Viral Vector Forms</b>	<ul style="list-style-type: none"><li>Reassortant delta-NSs/delta-NSm orthobunyaviruses</li></ul>
<b>NIH Guidelines Section</b>	III-D-3
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL3
<b>Discussion</b>	This is an update of a previously approved project. They are requesting to add reassortant $\Delta$ NSs/ $\Delta$ NSm orthobunyaviruses and are planning to do the work at BSL3. All PPE, containment and decontamination procedures are appropriate. No concerns noted.
<b>Verification of training</b>	All training is up to date.
<b>Verification of facilities</b>	The Lab is up to date on inspections.
<b>Motion</b>	A motion was made to approve the project as written.
<b>Vote</b>	The motion was unanimously approved.
<b>b. PI name/Lab</b>	<b>Lark Lab</b>
<b>Project Number and Title</b>	<b>26-014B: Skeletal Muscle Trafficking of Extracellular Vesicles</b>
<b>Project Overview</b>	This project involves transducing immortalized murine skeletal muscle myoblasts (C2C12) with a lentivirus to drive overexpression of the tetraspanin CD81 fused to green fluorescent protein (GFP) or a control lentivirus that only expressed GFP.
<b>Planned Modifications</b>	transducing immortalized murine skeletal muscle myoblasts (C2C12) with a lentivirus
<b>Agents used</b>	<ul style="list-style-type: none"><li>Lentiviral vectors</li></ul>
<b>NIH Guidelines Section</b>	III-D-1; III-D-3
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL2

<b>Discussion</b>	<p>1) Please specify bleach concentration and when it will be used--end of experiment.</p> <p>2) Specify what type(s) eye protection will be used.</p> <p>3) For biological materials "stored for biohazard bag", specify that materials will be autoclaved at the completion of the experiment and specify what will be done to solid waste beyond biologicals (anything else that is in contact with the lentivirus/cells).</p> <p>4) Define RIPA buffer. Does it destroy lentiviruses?</p> <p>5) What will the cells be passage into? C2C12 cells?</p>
<b>Verification of training</b>	All training is up to date.
<b>Verification of facilities</b>	The Lab is up to date on inspections.
<b>Motion</b>	A motion was made to approve the project with modifications described above (see Discussion).
<b>Vote</b>	The motion was unanimously approved.
<b>c. PI name/Lab</b>	<b>Schorr Lab</b>
<b>Project Number and Title</b>	<b>26-016B: Oral vaccination of bats against white-nose syndrome</b>
<b>Project Overview</b>	The Colorado Natural Heritage Program monitors populations of bats throughout Colorado and western US. Many species are susceptible to white-nose syndrome, which is caused by the fungus, <i>Pseudogymnoascus destructans</i> (Pd). Because the disease has killed bats by the millions, our collaborators may ask us to administer the vaccine, which is a raccoon poxviruses (RCN) expressing Pd calnexin (CAL) and serine protease (SP) to bats at roost we monitor.
<b>Planned Modifications</b>	Administration of virally-vectored vaccine candidate to bats
<b>Agents used</b>	<ul style="list-style-type: none"> <li>white-nose syndrome vaccine (recombinant raccoon poxviruses (RCN) expressing <i>Pseudogymnoascus destructans</i> calnexin (CAL) and serine protease (SP)</li> </ul>
<b>NIH Guidelines Section</b>	III-D-4
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL1
<b>Discussion</b>	<ol style="list-style-type: none"> <li>Is there any manipulation of guano samples at CSU, or are they sent out for analysis as is? If there is manipulation, a lab visit may be required.</li> <li>Is PPE decontaminated before disposal?</li> <li>Please briefly describe "white-nose syndrome decontamination protocol guidelines".</li> <li>Are annual antibody titers of personnel required for rabies virus?</li> </ol>
<b>Verification of training</b>	Annual Biosafety Training required for some personnel
<b>Verification of facilities</b>	Lab visit may be required depending on response to questions above

<b>Motion</b>	A motion was made to approve the project with modifications described above (see Discussion).
<b>Vote</b>	The motion was unanimously approved.
<b>d. PI name/Lab</b>	<b>Dean Lab</b>
<b>Project Number and Title</b>	<b>26-017B: A novel oral subunit vaccine against highly pathogenic avian influenza in poultry</b>
<b>Project Overview</b>	The purpose of this agreement is to develop a novel vaccine to protect poultry from highly pathogenic avian influenza (HPAI) using the probiotic, Lactobacillus acidophilus, as a platform.
<b>Planned Modifications</b>	Construct vaccine candidates using the probiotic, Lactobacillus acidophilus, as a platform
<b>Agents used</b>	<ul style="list-style-type: none"> <li>• Lactobacillus acidophilus</li> <li>• Lactobacillus spp</li> </ul>
<b>NIH Guidelines Section</b>	III-D-2; III-D-4
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL-2; ABL2
<b>Discussion</b>	<p>1) Will other disinfectants be used in addition to 70% ethanol?</p> <p>2) What will be used for facility disinfection?</p> <p>3) The project summary references a challenge study; however, this is not described in the Experimental and Procedural Details. Please describe the challenge model and specify whether it will be conducted by the Dean Lab or a collaborator.</p>
<b>Verification of training</b>	All training is up to date.
<b>Verification of facilities</b>	The Lab is up to date on inspections.
<b>Motion</b>	A motion was made to approve the project with modifications described above (see Discussion).
<b>Vote</b>	The motion was unanimously approved.
<b>e. PI name/Lab</b>	<b>Roberts Lab</b>
<b>Project Number and Title</b>	<b>26-018B: Characterizing and investigating the emergence of Pantoea species wheat pathogens</b>
<b>Project Overview</b>	This project investigates the basic biology of the Pantoea species (P. agglomerans and P. allii), including the environmental conditions required for pathogenicity, analyzes the genetic differences between pathogenic and non-pathogenic isolates, the host range, and the bacterial inoculum levels required for disease.
<b>Planned Modifications</b>	
<b>Agents used</b>	5. Pantoea species (P. agglomerans and P. allii)
<b>NIH Guidelines Section</b>	III-E
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL-1; BSL1-P
<b>Discussion</b>	This is a straightforward project, studying the pathology of Pantoea species in plants. All materials will be autoclaved or

	treated with Greenshield. All permits are in place. No concerns were expressed about this project.
<b>Verification of training</b>	Personnel needs to complete the Shipping training.
<b>Verification of facilities</b>	The Lab is up to date on inspections.
<b>Motion</b>	A motion was made to approve the project as written.
<b>Vote</b>	The motion was unanimously approved.

#### 4. Amendments requiring full IBC review

<b>f. PI name/Lab</b>	<b>Schountz Lab</b>
<b>Project Number and Title</b>	<b>13-098B: Manipulation of host cell responses by New World hantaviruses</b>
<b>Project Overview</b>	The focus of this project is to characterize the activities of hantaviruses in deer mouse and human cells, including dendritic cells.
<b>Planned Modifications</b>	NA
<b>Agents used</b>	<ul style="list-style-type: none"> <li>Andes virus</li> </ul>
<b>NIH Guidelines Section</b>	NA
<b>Proposed containment conditions (BSL, ABSL, etc.)</b>	BSL3/ABSL3
<b>Amendment request</b>	Adding in vivo work in deer mice with Andes virus
<b>Discussion</b>	<ol style="list-style-type: none"> <li>What is the route and dose of exposure for the deer mice?</li> <li>Handle animals in a BSC should be changed to Y for the laboratory infections.</li> <li>Please describe this new part of the study in the overview, including how long the mice will be monitored for infection and how many time experimental infections will be conducted.</li> <li>Please confirm that infected deer mice will remain at ABSL3 and include the statement: deer mice are not permissible to chronic infection with Andes virus and therefore do not meet the criteria outlined in BMBL requiring BSL-4.</li> </ol>
<b>Verification of training</b>	All training is up to date.
<b>Verification of facilities</b>	The Lab is up to date on inspections.
<b>Motion</b>	A motion was made to approve the project with modifications described above (see Discussion).
<b>Vote</b>	The motion was unanimously approved.

#### 6. New Business

##### a. IBC Membership updates

The IBC/IRE Manager presented several updates for new membership for the committee to consider:

- Chair/Associate Chair transition – beginning July 1, Dr. Chaoping Chen will be stepping down as IBC Chair, and staying on the committee as a regular member.

As the Associate Chair, Dr. Angela Bosco-Lauth will assume the role as Chair on July 1<sup>st</sup>. The committee will need to nominate a new Associate Chair.

- ii. New non-affiliated – Community member, Dan Frazen, has expressed difficulty attending in-person meetings, and is considering not renewing his membership. The committee will need to look at recruiting a new community member. There was discussion regarding the requirements for this position. The two main requirements are that they must be local (within 50 miles) and must not be affiliated (or have close family members affiliated) with CSU. The committee was encouraged to think about people they know who might be interested and to forward their information to the IBC/IRB Manager.
- iii. Adding another plant expert – The IBC previously had 2 plant experts on the committee and for the past couple of years there has only been one. It was suggested that the committee consider recruiting an additional plant person who could assist with reviews of plant research, and to perhaps look at someone from a different department to broaden representation on the committee. The committee agreed this would be a good idea and were asked to forward any potential candidates to the IBC/IRE manger.

## 7. Unfinished Business

### a. NIH Initiative to Modernize and Strengthen Biosafety Oversight

(<https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/>)

No updates

## 8. Closed Session

The meeting was closed briefly to discuss personal, proprietary, and/or security matters not subject to the NIH Guidelines.

## 9. Reports

<b>a. Coordinator's Report</b>	1. Next IBC meeting: Wednesday, May 13, 2026 2. A survey will be sent out regarding summer meeting times
<b>b. Biosafety Office Report</b>	1. Inspections update: 2. Incident Reports: no incident involving rDNA during this period.

## 10. Public Comment

There was a question from a public member regarding the white nose vaccine discussed in one of the above projects. They asked whether the vaccine was a liquid or a paste. One of the committee members confirmed that it was liquid that is dripped into the mouth of a bat.

**11. Items to be read into the minutes**

<p><b>a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed</b></p>	<p><b>a. Easley Lab</b> <b>Project:</b> <u>ARPA-H Washington University - Porcine NITRO Dosing Study (26-011B)</u>; BSL2/ABSL2; NIH Guidelines category non-exempt rDNA: III-D-4; III-E</p> <p><b>b. Leach (Jan) Lab</b> <b>Project:</b> <u>Identification of traits in Bacillus subtilis for survival in the air (26-012B)</u>; BSL1; NIH Guidelines category non-exempt rDNA: III-E</p> <p><b>c. MacNeill Lab</b> <b>Project:</b> <u>Evaluation of an oncolytic virus (MYXVorfC) adjunct therapy to prevent recurrence of canine soft tissue sarcomas (26-010B)</u>; BSL2/ABSL2; NIH Guidelines category non-exempt rDNA: III-D-1; III-D-4</p>
--	--